

SQ Sequence 223 AA;

Query Match 58.0%; Score 792.5; DB 22; Length 223;
Best Local Similarity 66.8%; Pred. No. 1e-68;
Matches 147; Conservative 0; Mismatches 0; Indels 73; Gaps 1;

QY 1 MLWRLIYWQLLALFFLPFCLODEYME----- 28
DB 1 MLWRLIYWQLLALFFLPFCLODEYME----- 28
QY 29 -----SPOTGLPPDCSKCHGY 47
DB 61 SHPTGTVDNNTSLKSLRPDELPHPEVDDLAQITTFWGSQPTGLPPDCSKCHGY 120
QY 48 SFYGYQPPGPPGPGIPGNGHNGNGATGHEGAKGDKDGLGPRGERGQHPKGBK 107
DB 121 SFYGYQPPGPPGPGIPGNGHNGNGATGHEGAKGDKDGLGPRGERGQHPKGBK 180
QY 108 GYPIPELQIAFMASLATHFSNQNSGIIFSSVETNIGNF 147
DB 181 GYPIPELQIAFMASLATHFSNQNSGIIFSSVETNIGNF 220

RESULT 11
ID AAY11485 standard; Protein; 128 AA.
XX AAY11485;
AC AAY11485;
XX
DT 21-JUN-1999 (first entry)
XX
DE Human 5' EST secreted protein SEQ ID NO 307.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX Homo sapiens.
OS
XX
PN WO9906551-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01235.
XX
PR 01-AUG-1997; 97US-0905133.
XX
PA (GEST) GENSET.
XX
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
XX WPI; 1999-153781/13.
DR N-PSDB; AAX39551.
XX
XX New nucleic acids encoding human secreted - proteins obtained from
PT cDNA libraries prepared from substantia nigra, cerebellum, surrenals
XX and fetal brain tissue
XX
PS Claim 34; Page 402-403; 43app; English.
XX
XX AAX39440 to AAX39597 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins, and encode the proteins given in AAY11374 to
CC AAY11531, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
PT regulating activity, chemotactic/ chemokinetic activity, haemostatic and

CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
XX polypeptide into a membrane, or importing a polypeptide into a cell.
SQ Sequence 128 AA;

Query Match 52.7%; Score 721; DB 20; Length 128;
Best Local Similarity 100.0%; Pred. No. 4.2e-62;
Matches 124; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWRLIYWQLLALFFLPFCLODEYME----- 60
DB 1 MLWRLIYWQLLALFFLPFCLODEYME----- 60
QY 61 PPGIPGNGHNGNGATGHEGAKGDKDGLGPRGERGQHPKGBK 120
DB 61 PPGIPGNGHNGNGATGHEGAKGDKDGLGPRGERGQHPKGBK 120
QY 121 MASL 124
DB 121 MASL 124

RESULT 12
ID AAM40074 standard; Protein; 126 AA.
XX AAM40074;
AC AAM40074;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 3219.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
XX leukaemia.
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
XX
PR 25-APR-2000; 2000US-052317.
XX
PR 09-JUL-2000; 2000US-0598042.
XX
PR 19-JUL-2000; 2000US-0620312.
XX
PR 03-AUG-2000; 2000US-0653450.
XX
PR 14-SEP-2000; 2000US-0662191.
XX
PR 19-OCT-2000; 2000US-0693036.
XX
PR 29-NOV-2000; 2000US-0727344.
XX
XX (HYSE-) HYSEQ INC.
XX
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
XX WPI; 2001-442253/47.
DR N-PSDB; AAI59230.
XX
XX Novel nucleic acids and polypeptides, useful for treating disorders.
PT such as central nervous system injuries -
XX

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 10:42:48 ; Search time 15 Seconds
(without alignments)
482.536 Million cell updates/sec

Title: US-09-931-836-2
Perfect score: 1367
Sequence: 1 MLNRQLIYWOLLALFLFPFC.....LHGDHQRSTFAGFLFETK 246

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database :
- 1: /cgn2_6/ptodata/1/iaa/5A.COMB.pcp.*
 - 2: /cgn2_6/ptodata/1/iaa/5B.COMB.pcp.*
 - 3: /cgn2_6/ptodata/1/iaa/6A.COMB.pcp.*
 - 4: /cgn2_6/ptodata/1/iaa/6B.COMB.pcp.*
 - 5: /cgn2_6/ptodata/1/iaa/PCTUS.COMB.pcp.*
 - 6: /cgn2_6/ptodata/1/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	582	42.6	105	4	US-09-188-930-147
2	582	42.6	105	4	US-09-188-930-280
3	316	23.1	294	4	US-09-188-930-294
4	294	21.5	247	2	US-08-463-911-2
5	293.5	21.5	231	4	US-09-530-423-2
6	293.5	21.5	244	2	US-08-463-911-7
7	293.5	21.5	244	4	US-09-140-804-3
8	293.5	21.5	244	4	US-09-336-536-20
9	293.5	21.5	244	4	US-09-530-423-1
10	287	21.0	247	4	US-09-140-804-8
11	287	21.0	247	4	US-09-118-408-3
12	287	21.0	247	4	US-09-506-855-3
13	274	20.0	246	2	US-08-463-911-4
14	273	20.0	746	4	US-09-370-838-185
15	264.5	19.3	228	4	US-09-336-536-4
16	264.5	19.3	243	4	US-09-140-804-2
17	264.5	19.3	243	4	US-09-336-536-3
18	254.5	18.6	243	4	US-09-336-536-10
19	252.5	18.5	228	4	US-09-336-536-11
20	252.5	18.5	243	4	US-09-188-930-295
21	237.5	17.4	281	4	US-09-118-408-44
22	237.5	17.4	281	4	US-09-506-855-44
23	226	16.5	281	4	US-09-118-408-2
24	226	16.5	281	4	US-09-506-855-2
25	226	16.5	423	1	US-08-383-744-2
26	226	16.5	423	2	US-08-999-336-2
27	226	16.5	423	5	PCT-US96-01427-2

28	219	16.0	245	4	US-09-140-804-4	Sequence 4, Appli
29	202	14.8	215	4	US-09-140-804-5	Sequence 5, Appli
30	200.5	14.7	198	4	US-09-188-930-138	Sequence 138, App
31	196	14.3	222	4	US-09-140-804-7	Sequence 7, Appli
32	194	14.2	185	2	US-08-463-911-3	Sequence 3, Appli
33	192	14.0	623	4	US-09-029-348-3	Sequence 3, Appli
34	192	14.0	626	4	US-09-029-348-2	Sequence 2, Appli
35	186	13.6	236	4	US-09-140-804-6	Sequence 6, Appli
36	185	13.5	357	1	US-07-609-716-66	Sequence 66, Appli
37	185	13.5	357	1	US-08-642-255-33	Sequence 33, Appli
38	185	13.5	357	1	US-08-475-411A-66	Sequence 66, Appli
39	185	13.5	357	1	US-08-478-029A-66	Sequence 66, Appli
40	184.5	13.5	684	1	US-08-555-669-12	Sequence 12, Appli
41	184.5	13.5	684	3	US-09-073-663-12	Sequence 12, Appli
42	183.5	13.4	532	1	US-08-494-168-9	Sequence 9, Appli
43	183	13.4	489	2	US-08-794-795-7	Sequence 7, Appli
44	183	13.4	489	4	US-09-249-200-7	Sequence 7, Appli
45	183	13.4	518	1	US-08-392-367B-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-09-188-930-147
; Sequence 147, Application US/09188930A
; Patent No. 6150502
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James Greg
; TITLE OF INVENTION: Compositions Isolated From Skin Cells
; FILE REFERENCE: 11000.1011c1
; CURRENT FILING DATE: 1998-11-09
; NUMBER OF SEQ ID NOS: 348
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 147
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Rat
US-09-188-930-147

Query Match	42.6%	Score 582;	DB 4;	Length 105;
Best Local Similarity	93.3%	Pred. No. 2.1e-51;		
Matches	98;	Conservative	2;	Mismatches 5; Indels 0; Gaps 0;
OY	1	MLNRQLIYWOLLALFLFPFC	CODEYMESPTGGLPPDCSCCHGDY	SFRGYQGGPPPG 60
DB	1	MLNRQLIYWOLLALFLFPFC	CODEYMESPTGGLPPDCSCCHGDY	SFRGYQGGPPPG 60
OY	61	PPGPNHNGNNGATGHEGAKGKDGKDLGPRGERGQHGPKG	105,	
DB	61	PPGPNHNGNNGATGHEGAKGKDGKDLGPRGERGQHGPKG	105	

RESULT 2
US-09-188-930-280
; Sequence 280, Application US/09188930A
; Patent No. 6150502
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James Greg
; TITLE OF INVENTION: Compositions Isolated From Skin Cells
; FILE REFERENCE: 11000.1011c1
; CURRENT APPLICATION NUMBER: US/09/188,930A

; CURRENT FILING DATE: 1998-11-09
; NUMBER OF SEQ ID NOS: 348
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 280
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Rat
; US-09-188-930-280

Query Match 42.6%; Score 582; DB 4; Length 105;
Best Local Similarity 93.3%; Pred. No. 2.1e-51;
Matches 98; Conservative 2; Mismatches 5; Indels 0; Gaps 0;
Qy 1 MLRQLIYQALLALFFLPCLQDYMESPTQGLPPDCSKCHGDSFRGYQGPPGPPG 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 MLRQLVYVHLLALLFLPCLQDYMESPOAGGLPPDCSKCHGDSFRGYQGPPGPPG 60
Qy 61 PPGIPGNHGNNGNATGHEGAKGDKGDLGPRGRGQHPKG 105
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 PPGIPGNHGNNGNATGHEGAKGDKGDLGPRGRGQHPKG 105

RESULT 3

US-09-188-930-294
; Sequence 294; Application US/09188930A

; Patent No. 6150502

; GENERAL INFORMATION:

; APPLICANT: Watson, James D.

; APPLICANT: Strachan, Lorna

; APPLICANT: Sleeman, Matthew

; APPLICANT: Onrust, Rene

; APPLICANT: Murison, James Greg

; TITLE OF INVENTION: Compositions Isolated From Skin Cells

; FILE OF INVENTION: and Methods For Their Use

; FILE REFERENCE: 11000.1011c1

; CURRENT APPLICATION NUMBER: US/09/188,930A

; CURRENT FILING DATE: 1998-11-09

; NUMBER OF SEQ ID NOS: 348

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 294

; LENGTH: 294

; TYPE: PRT

; ORGANISM: Rat

; US-09-188-930-294

Query Match 23.1%; Score 316; DB 4; Length 294;
Best Local Similarity 28.9%; Pred. No. 5.7e-24;
Matches 86; Conservative 41; Mismatches 89; Indels 82; Gaps 12;

Qy 6 LIYQALLALFFLPCLQDYM-----ESPTGGLPPDCSKCHGDSFRGYQGPPGPP 59
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 10 MISWLLAC-ALP---CAADPMLGAFARRDPKGGPQLVCS-----LPGQGP 54
Qy 60 GPPGIPGNHGNNGNATGHEGAKGDKG-----PELQIAFMASLATHFSNQNS 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 55 GPPAPSGSGVMGMPGPKGDKGQDQDGRDSEEGPPTGNGKQGPKGKAGATGRA 114
Qy 93 GPRGER-----GQHPKRGKGYGP-----PELQIAFMASLATHFSNQNS 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 115 GPRGPKGVSGTPGKHGTPGKKGKGEPLPGPCSGSGSRAKSAFSAVTKSYPERL 174
Qy 134 GIIFSSVETNIGNFDVMTGFRGAPVSGVYFFTSMM---KHEDVEEYVYLMHNGNTVF 190
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 175 PIKFDKILMNEGGHYNASSGKGVSVPGIYFTYDITLANKH-----LAIGLVHNGQ--Y 227
Qy 191 SMYSYEMK-GRSDTSSNHAHLKAKGDEWLMR---GNGALHGDHQRFSFAGFLFP 243
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 228 RIRFDANTGNHDVAGSTILAKGDEWLMQIFYSRONGLFYDPYWTDSLFTGLIY 285

RESULT 4

US-08-463-911-2

; Sequence 2; Application US/08463911

; Patent No. 5869330
; GENERAL INFORMATION:
; APPLICANT: Scherer, Philipp E.
; APPLICANT: Lodish, Harvey F.
; TITLE OF INVENTION: A NOVEL SERUM PROTEIN PRODUCED
; TITLE OF INVENTION: EXCLUSIVELY IN ADIPOCYTES
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Millitia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,911
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WHI95-05
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 247 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-463-911-2

Query Match 21.5%; Score 294; DB 2; Length 247;

Best Local Similarity 31.5%; Pred. No. 7.4e-22;

Matches 81; Conservative 40; Mismatches 102; Indels 34; Gaps 9;

Qy 6 LIYQALLALFFLPCLQDYMESPTQGG--LPDPCKCHGDSFRGYQGPPGPPG 63
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 2 LLQALLFLILP-SHAEDDVTTTEELAPALVPPPKTCA-----GWMA-----GIPG 48
Qy 64 IPGNHGNNGNATGHEGAKGDKGDLGPRGER---GQHPKRGKGYGPPIPE----- 115
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 49 HPGNHGTGPRDGRDTPGKGEKGDAGLLGPKGETGDMGTGAEGRGFPCTPKRGKGP 108
Qy 116 -----LQIAFMASLATHFSNQNSGIIFSSVETNIGNFDVMTGFRGAPVSGVYFFTSMM 170
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 109 EAYMYKSAFVSGLETRVTPVNPVIRFTKIFYNOONHYDGTGKFNIPGLYFSYHIT 168
Qy 171 KHEDVEEYVYLMHNGNTVFSMYSENKSGKSSNHAHLKAKGDEWLMR-GNG---A 226
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 169 VY--MKDVYSLFKKAKVLTVDYQYQEKVNDQASGVSLLHLEVGDQVQLVYGDGHNG 226
Qy 227 LHGDHQRFSFAGFLFP 243
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 227 LYADNVNDSTFTGLLY 243

RESULT 5

US-09-530-423-2

; Sequence 2; Application US/09530423

; Patent No. 6461821

; GENERAL INFORMATION:

; APPLICANT: Otsuka Pharmaceutical Co., Ltd.

; TITLE OF INVENTION: Smooth muscle growth inhibitory composition, a

; TITLE OF INVENTION: Diagnostic method for arteriosclerosis and a kit

; TITLE OF INVENTION: therefor

; FILE REFERENCE: P98-51

Example 5; SEQ ID NO 3219; 10078pp; English.

The invention relates to human nucleic acids (AA157798-RA161369) and the encoded polypeptides (AA38642-RA42213) with nootropic, immunosuppressant and cytostatic activity. The polynucleotides are useful in gene therapy. A composition containing a polypeptide or polynucleotide of the invention may be used to treat diseases of the peripheral nervous system, such as peripheral neuropathies, peripheral neuropathy and localised neuropathies and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager Syndrome. Other uses include the utilisation of the activities such as: immune system suppression, Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, cancer diagnosis and therapy, drug screening, assays for receptor activity, arthritis and inflammation, leukaemias and C.N.S disorders.

Note: The sequence data for this patent did not form part of the printed specification.

Sequence 126 AA;

Query Match 48.5%; Score 663; DB 22; Length 126;
Best Local Similarity 100.0%; Pred. No. 1.8e-56;
Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 121 MASLATHFSNQSGIFSSVETNIGNFFDVTMGREGAPVSGVYFFTFSMKHEDEVYV 180

Db 1 MASLATHFSNQSGIFSSVETNIGNFFDVTMGREGAPVSGVYFFTFSMKHEDEVYV 60

Qy 181 YLMHNGNTVFSMYSEMGKSDTSSNHAVLKLAKGDEWLRMGNGALHGDHQRFTFAGF 240

Db 61 YLMHNGNTVFSMYSEMGKSDTSSNHAVLKLAKGDEWLRMGNGALHGDHQRFTFAGF 120

Qy 241 LLFETK 246

Db 121 LLFETK 126

RESULT 13

AA1575969

ID AA1575969 standard; Protein; 105 AA.

AC AA1575969;

DT 27-MAR-2000 (first entry)

DE Rat skin cell protein, SEQ ID 147.

KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
KW secreted; transmembrane; inflammation; cancer; neurological disease;
KW angiogenesis; tumour vascularisation; growth disorder;
KW developmental disorder; skin wound; hair follicle disorder;
KW anti-inflammatory; cytostatic; neuroprotective; vulnery.

OS Rattus sp.

XX WO9955865-A1.

XX 04-NOV-1999.

XX 29-APR-1999; 99WO-NZ00051.

XX 29-APR-1998; 98US-0069726.

XX 09-NOV-1998; 98US-0188930.

XX (GENE-) GENESIS RES & DEV CORP LTD.

XX Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;

XX WPI: 2000-072177/06.

XX Novel polynucleotides useful for the treatment of various conditions

including wounds and cancer -

Claim 4; Page 112-113; 235pp; English.

The invention relates to novel nucleic acid sequences derived from rat dermal papilla, human keratinocytes and neonatal foreskin fibroblasts, and mouse embryonic skin, keratinocyte stem cells and transit amplifying cells. Polypeptides of the invention may be used to treat inflammation, cancer and neurological diseases. The proteins may be used to stimulate the growth and motility of keratinocytes, to inhibit the growth of cancer cells, to modulate angiogenesis and tumour vascularisation, to modulate skin inflammation, to modulate epithelial cell growth and to inhibit binding of HIV-1 to leukocytes. The invention may also be used to treat growth and developmental defects, skin wounds and hair follicle disorders. Sequences AA1575942-Y76123 represent polypeptides encoded by cDNA sequences derived from several mouse, rat or human skin cell types. Sequences AA1575942-Y75947, AA1576020-Y76021, AA1576094-Y76104 and AA1576119 are proteins with an N-terminal signal sequence, indicating that they are secreted. Sequences AA1575986-Y75989, AA1576061-Y76071, AA1576106-Y76109 and AA1576121-Y76122 are proteins with one or more putative transmembrane domains.

Sequence 105 AA;

Query Match 42.6%; Score 582; DB 21; Length 105;

Best Local Similarity 93.3%; Pred. No. 1e-48;

Matches 98; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 1 MLWQLIYWQLLALFFLPCLCQDEYMESPTGGLPPDCSKCHGDYSFRGYQGP 60

Db 1 MLRQLVWHLLALLFLPCLCQDEYMESPTGGLPPDCSKCHGDYSFRGYQGP 60

Qy 61 PPGIPGHNNGNNGATGCHGAKGKDGKDLGPRGERGQHGPKG 105

Db 61 PPGIPGHNNGNNGATGCHGAKGKDGKDLGPRGERGQHGPKG 105

RESULT 14

AA1576025

ID AA1576025 standard; Protein; 105 AA.

AC AA1576025;

DT 27-MAR-2000 (first entry)

DE Rat skin cell protein, SEQ ID NO:280.

KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
KW secreted; transmembrane; inflammation; cancer; neurological disease;
KW angiogenesis; tumour vascularisation; growth disorder;
KW developmental disorder; skin wound; hair follicle disorder;
KW anti-inflammatory; cytostatic; neuroprotective; vulnery.

OS Rattus sp.

XX WO9955865-A1.

XX 04-NOV-1999.

XX 29-APR-1999; 99WO-NZ00051.

XX 29-APR-1998; 98US-0069726.

XX 09-NOV-1998; 98US-0188930.

XX (GENE-) GENESIS RES & DEV CORP LTD.

XX Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;

XX WPI: 2000-072177/06.

XX Novel polynucleotides useful for the treatment of various conditions

XX